{"id":"W2943295610","doi":"10.1111/all.13850","title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","year":2019,"lang":"en","type":"article","venue":"Allergy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"GlaxoSmithKline","keywords":"Mepolizumab; Omalizumab; Medicine; Exacerbation; Asthma; Population; Clinical endpoint; Internal medicine; Physical therapy; Pediatrics; Clinical trial; Eosinophil; Immunology; Immunoglobulin E; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003543936,0.0001566152,0.0005283121,0.00007755837,0.00006067317,0.00001096036,0.0001623194,0.0001372004,0.0002217342],"category_scores_gemma":[0.0002539007,0.00009892523,0.0002617071,0.0001744971,0.0001055062,0.00005268442,0.00007289992,0.0002070653,0.00006771879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004870283,"about_ca_system_score_gemma":0.0002388071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001157314,"about_ca_topic_score_gemma":0.0003199141,"domain_scores_codex":[0.9982563,0.0001136486,0.0007179997,0.0003055641,0.0003049264,0.0003015642],"domain_scores_gemma":[0.9985288,0.000413783,0.0001972638,0.0006191853,0.00009887489,0.0001421332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02184785,0.002110603,0.6360916,0.000389359,0.001442417,0.0007009761,0.0007850797,0.0012199,0.003097387,0.0167795,0.006242052,0.3092933],"study_design_scores_gemma":[0.02156013,0.002030558,0.8152992,0.0004297683,0.00005571356,0.0001471104,0.0006516478,0.001207462,0.0003603765,0.0007215479,0.1571899,0.0003466093],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853067,0.001992344,0.000002141002,0.0006409618,0.0002968653,0.0004065489,0.000004730357,0.0000294252,0.01132029],"genre_scores_gemma":[0.9963726,0.0001817764,0.00003491582,0.000460249,0.0001705269,0.00001547257,0.000007758564,0.00002438182,0.002732335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3089467,"threshold_uncertainty_score":0.4034054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01248344375094616,"score_gpt":0.2917586319689213,"score_spread":0.2792751882179751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}